HRP20230379T1 - TETRAHIDROPIRANIL AMINO-PIROLOPIRIMIDINON ZA PRIMJENU U LIJEČENJU POREMEĆAJA POSREDOVANIH BTK-om - Google Patents
TETRAHIDROPIRANIL AMINO-PIROLOPIRIMIDINON ZA PRIMJENU U LIJEČENJU POREMEĆAJA POSREDOVANIH BTK-om Download PDFInfo
- Publication number
- HRP20230379T1 HRP20230379T1 HRP20230379TT HRP20230379T HRP20230379T1 HR P20230379 T1 HRP20230379 T1 HR P20230379T1 HR P20230379T T HRP20230379T T HR P20230379TT HR P20230379 T HRP20230379 T HR P20230379T HR P20230379 T1 HRP20230379 T1 HR P20230379T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- cancer
- use according
- lymphoma
- btk
- Prior art date
Links
- 230000001404 mediated effect Effects 0.000 title claims 4
- QBCYEGVJTIOUCK-UHFFFAOYSA-N 4-amino-6-(oxan-2-yl)pyrrolo[3,2-d]pyrimidin-2-one Chemical compound O1C(CCCC1)C1=CC=2C(C(=NC(N=2)=O)N)=N1 QBCYEGVJTIOUCK-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 21
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 10
- 206010025323 Lymphomas Diseases 0.000 claims 6
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 2
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 210000003679 cervix uteri Anatomy 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 210000000244 kidney pelvis Anatomy 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 208000003747 lymphoid leukemia Diseases 0.000 claims 2
- 210000000214 mouth Anatomy 0.000 claims 2
- 208000025113 myeloid leukemia Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 208000003200 Adenoma Diseases 0.000 claims 1
- 206010001233 Adenoma benign Diseases 0.000 claims 1
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 208000017701 Endocrine disease Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 206010023347 Keratoacanthoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 210000003445 biliary tract Anatomy 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000000133 brain stem Anatomy 0.000 claims 1
- 210000000621 bronchi Anatomy 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 230000001086 cytosolic effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 210000002768 hair cell Anatomy 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 210000003228 intrahepatic bile duct Anatomy 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000003849 large cell carcinoma Diseases 0.000 claims 1
- 210000002429 large intestine Anatomy 0.000 claims 1
- 210000000867 larynx Anatomy 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000000088 lip Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000003800 pharynx Anatomy 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 102200162764 rs1057519825 Human genes 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 208000000649 small cell carcinoma Diseases 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims 1
- 210000002105 tongue Anatomy 0.000 claims 1
- 208000010576 undifferentiated carcinoma Diseases 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 208000024051 villous adenoma of colon Diseases 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (17)
1. Spoj Formule (I):
[image]
ili farmaceutski prihvatljiva sol, tautomer, solvat, ili polimorf istog, za primjenu u postupku liječenja poremećaja posredovanog BTK-om ili moduliranja BTK, pri čemu BTK je mutant BTK, poželjno BTK C481S mutant.
2. Spoj za primjenu prema zahtjevu 1, pri čemu spoj je Formule (I):
[image]
ili farmaceutski prihvatljiva sol istog.
3. Spoj za primjenu prema zahtjevu 1, pri čemu spoj je Formule (I):
[image]
4. Spoj za primjenu prema zahtjevu 1, pri čemu je spoj prisutan kao farmaceutska kompozicija koja sadrži spoj ili farmaceutski prihvatljivu sol, tautomer, solvat, ili polimorf istog, i farmaceutski prihvatljiv razblaživač, ekscipijens ili nosač.
5. Spoj za primjenu u skladu sa zahtjevom 1, pri čemu je poremećaj posredovan BTK-om odabran od imunoloških poremećaja, raka, kardiovaskularnih bolesti, virusnih infekcija, inflamacije, poremećaja metabolizma/endokrine funkcije i neuroloških poremećaja.
6. Spoj za primjenu u skladu sa zahtjevom 5, pri čemu je rak odabran od raka dojke, jajnika, grlića materice, prostate, testisa, genitourinarnog trakta, jednjaka, larinksa, želuca, kože, pluća, kosti, kolona, gušterače, tiroidne žlijezde, bilijarnog trakta, vlasastih stanica, bukalne šupljine, nazofaringealnog, ždrijela, usne, jezika, usta, tankog crijeva, kolon-rektuma, debelog crijeva, rektuma, mozga i centralnog živčanog sustava, bronhija, jetre, intrahepatičnog žučnog kanala, bubrega i bubrežne karlice, mokraćnog mjehura, tijela materice, grlića materice, ili usne duplje, glioblastoma, neuroblastoma, keratoakantoma, epidermoidnog karcinoma, krupnostaničnog karcinoma, nesitnostaničnog karcinoma pluća (NSCLC), sitnostaničnog karcinoma, adenokarcinoma pluća, adenoma, adenokarcinoma, folikularnog karcinoma, nediferenciranog karcinoma, papilarnog karcinoma, seminoma, melanoma, sarkoma, karcinoma mjehura, karcinoma jetre, karcinoma bubrega, mijeloidnih poremećaja, limfoma, Hodgkinove leukemije, hepatocelularnog raka, glioma/glioblastoma, endometrijalnog raka, multiplog mijeloma, akutne mijelogene leukemije, kronične mijelogene leukemije, limfocitne leukemije, kronične limfoidne leukemije (CLL), mijeloidne leukemije, ne-Hodgkinovog limfoma, i viloznog adenoma kolona.
7. Spoj za primjenu u skladu sa zahtjevom 6, pri čemu rak je kronična limfoidna leukemija (CLL).
8. Spoj za primjenu u skladu sa zahtjevom 6, pri čemu rak je limfom.
9. Spoj za primjenu u skladu sa zahtjevom 8, pri čemu limfom je ne-Hodgkinov limfom.
10. Spoj za primjenu u skladu sa zahtjevom 8, pri čemu limfom je B-stanični limfom.
11. Spoj za primjenu u skladu sa zahtjevom 8, pri čemu limfom je anaplastični limfom krupnih stanica, primarni limfom centralnog živčanog sustava ili Waldenströmova makroglobulinemija.
12. Spoj za primjenu u skladu sa zahtjevom 6, pri čemu rak je mijeloidni poremećaji ili mijeloidna leukemija.
13. Spoj za primjenu u skladu sa zahtjevom 6, pri čemu je rak akutna mijeloidna leukemija.
14. Spoj za primjenu u skladu sa zahtjevom 6, pri čemu rak je multipli mijelom.
15. Spoj za primjenu u skladu sa zahtjevom 6, pri čemu rak je limfocitna leukemija.
16. Spoj za primjenu u skladu sa zahtjevom 6, pri čemu rak je sarkom ili tumor mozga.
17. Spoj za primjenu u skladu sa zahtjevom 5, pri čemu je poremećaj posredovan BTK-om reumatoidni artritis, sustavna i lokalna inflamacija, artritis, inflamacija povezana sa imuno supresijom, odbacivanje transplantiranog organa, alergije, ulcerativni kolitis, Kronova bolest, dermatitis, astma, sustavni eritematozni lupus, Sjögrenov sindrom, multipla skleroza, skleroderma/sustavna skleroza, idiopatska trombocitopenična purpura (ITP), vaskulitis povezan sa anti-neutrofilnim citoplazmatskim antitijelima (ANCA), kronična opstruktivna plućna bolest (COPD), ili psorijaza.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21165852.1A EP3882250B1 (en) | 2015-12-23 | 2015-12-23 | Tetrahydropyranyl amino-pyrrolopyrimidinone for use in treating btk-mediated disorders |
| PCT/US2015/000285 WO2017111787A1 (en) | 2015-12-23 | 2015-12-23 | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230379T1 true HRP20230379T1 (hr) | 2023-06-23 |
Family
ID=59090991
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230379TT HRP20230379T1 (hr) | 2015-12-23 | 2015-12-23 | TETRAHIDROPIRANIL AMINO-PIROLOPIRIMIDINON ZA PRIMJENU U LIJEČENJU POREMEĆAJA POSREDOVANIH BTK-om |
| HRP20210844TT HRP20210844T1 (hr) | 2015-12-23 | 2021-05-26 | Tetrahidropiranil amino-pirolopirimidinon i postupci njegove primjene |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210844TT HRP20210844T1 (hr) | 2015-12-23 | 2021-05-26 | Tetrahidropiranil amino-pirolopirimidinon i postupci njegove primjene |
Country Status (28)
| Country | Link |
|---|---|
| EP (2) | EP3394065B1 (hr) |
| JP (1) | JP6634520B2 (hr) |
| KR (2) | KR102547188B1 (hr) |
| CN (2) | CN113307811B (hr) |
| AU (3) | AU2015417922B2 (hr) |
| CA (1) | CA3008446C (hr) |
| CY (1) | CY1124210T1 (hr) |
| DK (2) | DK3394065T3 (hr) |
| ES (2) | ES2868884T3 (hr) |
| FI (1) | FI3882250T3 (hr) |
| HR (2) | HRP20230379T1 (hr) |
| HU (2) | HUE061761T2 (hr) |
| IL (2) | IL259938B (hr) |
| LT (2) | LT3882250T (hr) |
| MA (1) | MA56553B1 (hr) |
| MD (1) | MD3882250T2 (hr) |
| MX (1) | MX2018007815A (hr) |
| MY (1) | MY193177A (hr) |
| PH (1) | PH12018501390B1 (hr) |
| PL (2) | PL3882250T3 (hr) |
| PT (2) | PT3394065T (hr) |
| RS (2) | RS64141B1 (hr) |
| RU (1) | RU2715421C2 (hr) |
| SA (1) | SA518391836B1 (hr) |
| SG (1) | SG11201805154YA (hr) |
| SI (2) | SI3882250T1 (hr) |
| WO (1) | WO2017111787A1 (hr) |
| ZA (1) | ZA201804091B (hr) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190035925A (ko) | 2016-08-24 | 2019-04-03 | 아르퀼 인코포레이티드 | 아미노-피롤로피리미디논 화합물 및 이의 사용 방법 |
| CN109956870A (zh) | 2017-12-14 | 2019-07-02 | 南京卡文迪许生物工程技术有限公司 | 一种罗沙司他的合成方法及其中间体化合物 |
| AU2020283597A1 (en) * | 2019-05-31 | 2021-11-25 | Fochon Biosciences, Ltd. | Substituted pyrrolo (2, 3-b) pyridine and pyrazolo (3, 4-b) pyridine derivatives as protein kinase inhibitors |
| EP4059935A4 (en) * | 2019-11-13 | 2024-02-28 | Zhejiang Longcharm Bio-Tech Pharma. Co., Ltd. | PYRROLOPYRIMIDINE COMPOUND AS BTK INHIBITOR AND USE THEREOF |
| CN112812100B (zh) * | 2019-11-18 | 2022-04-05 | 四川海思科制药有限公司 | 一种具有降解btk激酶的化合物及其制备方法和药学上的应用 |
| JP7011638B2 (ja) * | 2019-12-16 | 2022-02-10 | アークル インコーポレイテッド | テトラヒドロピラニルアミノ－ピロロピリミジノンおよびその使用の方法 |
| CN112608318B (zh) * | 2019-12-16 | 2023-09-08 | 成都海博为药业有限公司 | 一种作为蛋白质激酶抑制剂的化合物及其用途 |
| MX2023005761A (es) * | 2020-11-17 | 2023-05-29 | Fochon Biosciences Ltd | Pirrolo [2,3-b] piridina sustituida y derivados de pirazolo [3,4-b] piridina como inhibidores de proteinas quinasas. |
| CN112574200B (zh) * | 2021-02-26 | 2021-06-11 | 安润医药科技（苏州）有限公司 | Btk和/或btk的突变体c481s的小分子抑制剂 |
| CN115028633B (zh) * | 2021-03-08 | 2023-12-22 | 药雅科技(上海)有限公司 | 吡咯并嘧啶类化合物的制备及其应用 |
| CN114761410B (zh) * | 2021-04-06 | 2023-08-25 | 广州必贝特医药股份有限公司 | 吡咯并嘧啶酮类化合物及其应用 |
| WO2022213932A1 (zh) * | 2021-04-06 | 2022-10-13 | 广州必贝特医药股份有限公司 | 吡咯并嘧啶酮类化合物及其应用 |
| CN117794934A (zh) | 2021-05-12 | 2024-03-29 | 浙江龙传生物医药科技有限公司 | 吡咯并嘧啶类化合物的晶型及其制备方法 |
| JP2025500886A (ja) | 2021-12-14 | 2025-01-15 | クロスファイアー オンコロジー ホールディング ビー．ヴイ． | 大環状ｂｔｋ阻害剤 |
| CN114409654A (zh) * | 2021-12-30 | 2022-04-29 | 安徽普利药业有限公司 | 一种btk抑制剂的中间体合成方法 |
| CN115894500B (zh) * | 2022-11-02 | 2024-05-28 | 中国药科大学 | 一种作为btk激酶抑制剂的化合物及其制备方法与用途 |
| CN118702697A (zh) * | 2023-03-18 | 2024-09-27 | 山东新时代药业有限公司 | 苯甲酰基吡咯并嘧啶类衍生物及其用途和制备方法 |
| CN116375715A (zh) * | 2023-04-06 | 2023-07-04 | 中国药科大学 | 一种作为非共价btk激酶抑制剂的化合物及其生物用途 |
| WO2024246287A1 (en) | 2023-06-02 | 2024-12-05 | Crossfire Oncology Holding B.V. | Medical use of a macrocyclic reversible btk inhibitor |
| WO2024245577A1 (en) | 2023-06-02 | 2024-12-05 | Netherlands Translational Research Center Holding B.V. | Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor |
| WO2024245578A1 (en) | 2023-06-02 | 2024-12-05 | Netherlands Translational Research Center Holding B.V. | Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor |
| WO2024256568A1 (en) | 2023-06-13 | 2024-12-19 | Crossfire Oncology Holding B.V. | Salt and crystal forms of a macrocyclic btk inhibitor |
| WO2024256574A1 (en) | 2023-06-13 | 2024-12-19 | Crossfire Oncology Holding B.V. | Process for preparing macrocyclic btk inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| WO2011063159A1 (en) | 2009-11-18 | 2011-05-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| US8377946B1 (en) * | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| WO2014164729A1 (en) * | 2013-03-12 | 2014-10-09 | Arqule, Inc. | Substituted tricyclic pyrazolo-pyrimidine compounds |
| EP2970300B1 (en) * | 2013-03-15 | 2018-05-16 | Boehringer Ingelheim International GmbH | Heteroaromatic compounds as btk inhibitors |
| GB201309085D0 (en) * | 2013-05-20 | 2013-07-03 | Redx Pharma Ltd | Compounds |
| GB201410430D0 (en) * | 2014-06-11 | 2014-07-23 | Redx Pharma Ltd | Compounds |
-
2015
- 2015-12-23 SI SI201531934T patent/SI3882250T1/sl unknown
- 2015-12-23 WO PCT/US2015/000285 patent/WO2017111787A1/en active Application Filing
- 2015-12-23 HU HUE21165852A patent/HUE061761T2/hu unknown
- 2015-12-23 MY MYPI2018001066A patent/MY193177A/en unknown
- 2015-12-23 RU RU2018126793A patent/RU2715421C2/ru active
- 2015-12-23 MA MA56553A patent/MA56553B1/fr unknown
- 2015-12-23 LT LTEP21165852.1T patent/LT3882250T/lt unknown
- 2015-12-23 PT PT159114909T patent/PT3394065T/pt unknown
- 2015-12-23 CA CA3008446A patent/CA3008446C/en active Active
- 2015-12-23 CN CN202110663289.5A patent/CN113307811B/zh active Active
- 2015-12-23 RS RS20230294A patent/RS64141B1/sr unknown
- 2015-12-23 JP JP2018533095A patent/JP6634520B2/ja active Active
- 2015-12-23 MD MDE20220501T patent/MD3882250T2/ro unknown
- 2015-12-23 ES ES15911490T patent/ES2868884T3/es active Active
- 2015-12-23 DK DK15911490.9T patent/DK3394065T3/da active
- 2015-12-23 RS RS20210646A patent/RS61887B1/sr unknown
- 2015-12-23 AU AU2015417922A patent/AU2015417922B2/en active Active
- 2015-12-23 SI SI201531588T patent/SI3394065T1/sl unknown
- 2015-12-23 PL PL21165852.1T patent/PL3882250T3/pl unknown
- 2015-12-23 KR KR1020187020899A patent/KR102547188B1/ko active IP Right Grant
- 2015-12-23 MX MX2018007815A patent/MX2018007815A/es unknown
- 2015-12-23 HR HRP20230379TT patent/HRP20230379T1/hr unknown
- 2015-12-23 FI FIEP21165852.1T patent/FI3882250T3/fi active
- 2015-12-23 HU HUE15911490A patent/HUE055221T2/hu unknown
- 2015-12-23 EP EP15911490.9A patent/EP3394065B1/en active Active
- 2015-12-23 PL PL15911490T patent/PL3394065T3/pl unknown
- 2015-12-23 DK DK21165852.1T patent/DK3882250T3/da active
- 2015-12-23 PT PT211658521T patent/PT3882250T/pt unknown
- 2015-12-23 CN CN201580085832.0A patent/CN108699062B/zh active Active
- 2015-12-23 EP EP21165852.1A patent/EP3882250B1/en active Active
- 2015-12-23 ES ES21165852T patent/ES2942743T3/es active Active
- 2015-12-23 PH PH1/2018/501390A patent/PH12018501390B1/en unknown
- 2015-12-23 SG SG11201805154YA patent/SG11201805154YA/en unknown
- 2015-12-23 KR KR1020237020794A patent/KR102746900B1/ko active IP Right Grant
- 2015-12-23 LT LTEP15911490.9T patent/LT3394065T/lt unknown
-
2018
- 2018-06-11 IL IL259938A patent/IL259938B/en active IP Right Grant
- 2018-06-19 ZA ZA2018/04091A patent/ZA201804091B/en unknown
- 2018-06-20 SA SA518391836A patent/SA518391836B1/ar unknown
-
2019
- 2019-03-13 AU AU2019201737A patent/AU2019201737B2/en active Active
-
2020
- 2020-06-04 AU AU2020203690A patent/AU2020203690B2/en active Active
-
2021
- 2021-04-22 IL IL282572A patent/IL282572B/en unknown
- 2021-05-26 HR HRP20210844TT patent/HRP20210844T1/hr unknown
- 2021-05-31 CY CY20211100469T patent/CY1124210T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210844T1 (hr) | Tetrahidropiranil amino-pirolopirimidinon i postupci njegove primjene | |
| IL300209A (en) | Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase | |
| HRP20210745T1 (hr) | Supstituirani spojevi tetrahidrokinolinona kao ror gama modulatori | |
| HRP20200681T1 (hr) | Ciklički eter pirazol-4-il-heterociklil-karboksamidni spojevi i postupci njihove upotrebe | |
| HRP20150858T1 (hr) | Inhibitori bromodomena i njihove uporabe | |
| HRP20210252T1 (hr) | Heterociklički amidi kao inhibitori kinaze | |
| HRP20192349T1 (hr) | Spojevi benzoksazepina i oksazolidinona i postupci njihove uporabe | |
| HRP20210036T1 (hr) | Soli inhibitora pi3k i postupci za njihovo dobivanje | |
| HRP20201954T1 (hr) | Metode liječenja kolestatskih i fibrotičnih bolesti | |
| CR20200532A (es) | Compuestos de heteroarilo tetracíclicos | |
| HRP20200767T1 (hr) | Humanizirana anti-humana cd19 protutijela i postupci uporabe | |
| UA111767C2 (uk) | Дигідропіримідинізохінолінони і фармацевтичні композиції, які їх містять, для лікування запальних порушень | |
| HRP20200478T1 (hr) | Farmakofor za indukciju faktora nekroze tumora (tnf) srodnog apoptoza-inducirajućeg liganda | |
| ZA201903985B (en) | Anti-bcma heavy chain-only antibodies | |
| JP2014520784A5 (hr) | ||
| RU2014121073A (ru) | Бициклические соединения пиперазина | |
| MX2017013382A (es) | Nuevas dihidropiridoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios. | |
| HRP20240658T1 (hr) | Novi postupci za ciljanje matičnih stanica raka | |
| RU2014121074A (ru) | Соединения 8-фторфталазин-1(2н)-она в качестве ингибиторов тирозинкиназы брутона | |
| HRP20201681T1 (hr) | Inhibitor aurora a kinaze | |
| MY189345A (en) | Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient | |
| HRP20171611T1 (hr) | N-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamidi i n-(4-hidroksi-4-metil-cikloheksil)-4-(2-piridil)-benzensulfonamidi i njihova terapeutska primjena | |
| PH12018500533A1 (en) | Pyrazolyl-substituted heteroaryls and their use as medicaments | |
| SI2953938T1 (en) | Functionalized benzopyran compounds and their use | |
| MX2018000945A (es) | Compuesto pirimidina de anillo fusionado, intermedio y metodo de preparacion, composicion y uso del mismo. |